Professor A. Graham Pockley
multimmune GmbH / Nottingham Trent University
Director / Professor of Immunobiology
Graham Pockley is the CEO of multimmune GmbH. multimmune’s unique and proprietary technology platform is based on the discovery (by Gabriele Multhoff and Claus Botzler) that a cell surface bound form of Hp70 is selectively, and widely expressed on on the plasma membranes of many tumour entities, and is developing innovative theranostics on the basis of this cell surface-expressed form of Hsp70.
Graham Pockley is also Professor of Immunobiology and Director of the John van Geest Cancer Research Centre (JvGCRC) at Nottingham Trent University. The JvGCRC uses integrated genomic, proteomic, immunological and bioinformatics platforms to identify biomarkers of disease and disease progression, predict therapeutic responses and develop diagnostic and immunotherapeutics. Programmes study the orchestration of innate and adaptive immunity in cancer, discover immunological and protein biomarkers of disease and therapeutic responses in cancer, and its findings inform the development and delivery of new diagnostic and immunotherapeutic strategies.
A new era of cancer therapeutics?
Despite progress, significant numbers of individuals continue to die of (by definition), aggressive, therapy-resistant disease. This Seminar will introduce a new approach for the treatment of aggressive cancer which has the potential to be used across the majority of cancer types, including rare cancers – ‘one drug could indeed fit all’.
EVEN MORE SEMINARS
Prof Samuel Janes University College London Hospitals
Dr Anita Rose The Raphael Hospital
Cognitive Issues in Multiple Sclerosis
Glenn Flux Royal Marsden Hospital
The emergence and resurgence of radiotherapeutics for cancer treatment
Emlyn Samuel Cancer Research UK
Brexit: getting the best outcome for research and patients
Philip Beer MRCP, FRCPath, PhD ONCODNA S.A
The evolution of oncology therapeutics in the genomic era.